- Record: found
- Abstract: found
- Article: not found
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
February 15 2017
February 15 2017
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Rosenberg and colleagues review evidence suggesting that T cells that target tumor neoantigens arising from cancer mutations are the main mediators of many effective cancer immunotherapies in humans.